Company Overview of AbGenomics International, Inc.
AbGenomics International, Inc., a biopharmaceutical company, focuses on the discovery and development of antibody therapeutics for the treatment of cancer and immune related inflammatory diseases. It offers AbGn-168, an immunomodulating investigational therapeutic antibody against CD162 that induces apoptosis of late-stage activated T cells and other immune cells, as well as spare naive, regulatory, and memory T cells; various animal disease models, such as CIA, NOD, and allergy, as well as transplantation rejection/GVHD in murine and DTH in non-human primate; and autoimmune diseases, including rheumatoid arthritis, Crohn's disease, lupus, and psoriasis. The company also provides antibody-7 ...
4984 El Camino Real
Los Altos, CA 94022
Founded in 2000
Key Executives for AbGenomics International, Inc.
Director of IP Management & Quality Assurance
Director of Project & Alliance Managements
Compensation as of Fiscal Year 2014.
AbGenomics International, Inc. Key Developments
AbGenomics International, Inc. Presents at 13th Annual BIO Investor Forum, Oct-08-2014 02:30 PM
Sep 9 14
AbGenomics International, Inc. Presents at 13th Annual BIO Investor Forum, Oct-08-2014 02:30 PM. Venue: The Palace Hotel, San Francisco, CA 94105, United States.
AbGenomics International, Inc. Presents at BioPharm America 2013, Sep-18-2013 03:15 PM
Aug 13 13
AbGenomics International, Inc. Presents at BioPharm America 2013, Sep-18-2013 03:15 PM. Venue: Westin Boston Waterfront Hotel, Boston, Massachusetts, United States.
AbGenomics International, Inc. Raises $9.6 Million in Financing
Jul 17 13
AbGenomics International, Inc. has raised $9.6 million in a financing round in private placement.
Similar Private Companies By Industry
Recent Private Companies Transactions
October 3, 2014
August 13, 2014